Evidence map›Paper›PMID 42225174›Full record

ArticleInternational journal of pharmaceutics2026

Macrocyclic histone deacetylase inhibitor-based near-infrared-responsive ionic nanomedicines for enhanced cancer therapy.

Adeniyi Oyebade, Md Riyad Hossain, Mahfuzul Hasan, Adeolu Oluremi, Md Shahedur Rahman, Nawab Ali, Robert J Griffin, Adegboyega K Oyelere, Noureen Siraj

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adeniyi OyebadeDepartment of Chemistry, University of Arkansas at Little Rock, Little Rock, AR 72204, USA.
Md Riyad HossainDepartment of Chemistry, University of Arkansas at Little Rock, Little Rock, AR 72204, USA.
Mahfuzul HasanDepartment of Chemistry, Philander Smith University, Little Rock 72202, USA.
Adeolu OluremiDepartment of Biology, University of Arkansas at Little Rock, Little Rock, AR 72204, USA.
Md Shahedur RahmanDepartment of Chemistry, University of Arkansas at Little Rock, Little Rock, AR 72204, USA.
Nawab AliDepartment of Biology, University of Arkansas at Little Rock, Little Rock, AR 72204, USA.
Robert J GriffinDepartment of Radiation Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
Adegboyega K OyelereSchool of Chemistry and Biochemistry, Parker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA 30332, USA.
Noureen SirajDepartment of Chemistry, University of Arkansas at Little Rock, Little Rock, AR 72204, USA. Electronic address: nxsiraj@ualr.edu.

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett · 2012 to 2026
$60.9M
NIGMS NIH HHS P20 GM103429
6 · The paper itself

Abstract

The integration of epigenetic therapy with photothermal treatment offers a promising strategy to enhance anticancer efficacy while minimizing systemic toxicity. Herein, we report the design and development of a novel class of ionic nanomedicines (INMs) synthesized from macrocyclic histone deacetylase inhibitors (mac-HDACis) and Near-Infrared (NIR) dye for combination cancer therapy. The mac-HDACi components, incorporating an N-(2-aminophenyl)acylamide Zinc-Binding Group (ZBG), were first protonated using acetic acid to yield the cationic compounds of mac-para HDACi and mac-meta HDACi. Using ionic-liquid chemistry, the resulting cationic compounds were electrostatically integrated with the NIR cyanine dye IR820 anion to generate two ionic materials (IMs), which were then converted into the INMs. The INMs, [mac-para HDACi][IR820] and [mac-meta HDACi][IR820], comprise the mac-HDACis (chemotherapeutic agents) and the photothermal therapeutic dye IR820. Dynamic Light Scattering (DLS) studies showed that the INMs were well-dispersed in aqueous media, with stable particle sizes (93.1-141 nm), low polydispersity indexes (PDIs), and high negative Zeta potential (ζ) values. Photophysical studies of the INMs revealed high molar absorptivity, red-shifted absorption, and higher non-radiative rate constants (k

Indexed as

Antineoplastic AgentsHistone Deacetylase InhibitorsMacrocyclic CompoundsCarbocyaninesCell Line, TumorHumansIndocyanine GreenInfrared RaysMCF-7 CellsNanomedicineNanoparticlesAntineoplastic AgentsCarbocyaninesHistone Deacetylase InhibitorsIndocyanine GreenIR 820Macrocyclic CompoundsApoptosisChemotherapyDrug deliveryEpigenetic therapyHistone deacetylase inhibitor (HDACi)Ionic nanomedicineNanoparticle characterizationNear-infrared (NIR)Photothermal therapy

Identifiers

PMID42225174
PMCPMC13374602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.